Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 2/20 | 0.46 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 5/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.42 |
| ▸ | GSK3B | P49841 | 4/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | PLK4 | O00444 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.41 |
| ▸ | PRKCG | P05129 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | LYN | P07948 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5215590 | 0.93 | CSNK1D (0.46) | CSNK1DMAPK10MAPK14MAPK13MAPK12 | |
| Ethyl Acetate SCHEMBL5875499 | 0.92 | EIF2AK2 (0.41) | CSNK1DEIF2AK2MAPK10MAPK14MAPK13 | |
| SCHEMBL5890649 | 0.87 | CSNK1D (0.51) | CSNK1DEIF2AK2MAPK10MAPK14MAPK13 | |
| SCHEMBL5891079 | 0.86 | CSNK1D (0.50) | CSNK1DEIF2AK2MAPK10MAPK14MAPK13 | |
| SCHEMBL5890640 | 0.85 | CSNK1D (0.49) | CSNK1DEIF2AK2MAPK10MAPK14MAPK13 | |
| SCHEMBL5890913 | 0.84 | CSNK1D (0.47) | CSNK1DEIF2AK2MAPK10MAPK14MAPK13 | |
| SCHEMBL5214973 | 0.83 | CSNK1D (0.51) | CSNK1DEIF2AK2MAPK10MAPK14MAPK13 | |
| SCHEMBL6182823 | 0.83 | GSK3B (0.59) | GSK3BCDK2 | |
| SCHEMBL5215526 | 0.83 | CSNK1D (0.47) | CSNK1DMAPK10MAPK14MAPK13MAPK12 | |
| SCHEMBL5214999 | 0.83 | EIF2AK2 (0.46) | CSNK1DEIF2AK2MAPK10MAPK14MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7034030-B2 | Pyralopyridines, process for their preparation and use as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-25 | — | — | US | claimed |
| US-7034030-B2 | Pyralopyridines, process for their preparation and use as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| US-20060058319-A1 | Pyrazolopyridines, process for their preparation and use as therapeutic compounds | ALBERTI MICHAEL J | 2006-03-16 | — | — | US | disclosed |
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
| US-20050059677-A1 | Pyralopyridines, process for their preparation and use as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059677-A1 | Pyralopyridines, process for their preparation and use as therapeutic compounds | CYP3A5, CYP3A4, CYP2C19 | CSNK1D 1070/4885EIF2AK2 3830/4885MAPK10 2668/4885 |
| US-20060058319-A1 | Pyrazolopyridines, process for their preparation and use as therapeutic compounds | CYP3A5, CYP3A4, CYP3A7 | CSNK1D 542/4885EIF2AK2 3578/4885MAPK10 2405/4885 |
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | QDPR, DPYD, ENTPD5 | CSNK1D 2789/4885EIF2AK2 57/4885MAPK10 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.